glp 1 molecule The Science Behind the Quest for a Non-Peptide Oral Weight Loss Drug | Office for Science and Society The challenge of developing oral
Description
Diabetes GLP-1s Show Better Retention but Still Leak Demand GLP-1 therapies prescribed for type 2 diabetes demonstrate stronger patient retention than those indicated for obesity, but the market still faces substantial leakage
How we eat matters too
And when that happens, the LMN steps in to confirm the diagnosis and justify the expense
In Pennsylvania, a $3.5 billion facility in Fogelsville, announced in January 2026 and beginning construction in 2026, will manufacture tirzepatide and next-generation peptides including retatrutide, with completion expected in 2031
